Bristol Myers Squibb Raises 2026 Revenue Forecast as Newer Drugs Drive Q3 Growth
The Bristol Myers Squibb Q3 2026 results lift revenue guidance as newer drugs grow 12%. EPS fell on a $1.6 billion charge.
Idiopathic Pulmonary Fibrosis Phase 3 Trial: 60 mg Wins
Idiopathic pulmonary fibrosis Phase 3 trial: admilparant 60 mg met its FVC goal in 1,255 patients, but 120 mg missed. What is known and what is not.
Bristol Myers Cancer Clinical Trial 2026: RYZ101 Meets Goal
Bristol Myers cancer clinical trial 2026: RYZ101 met its Phase 3 endpoint in neuroendocrine tumours, but the effect size and safety data are not yet public.
Hēlo Thrombectomy FDA Clearance: Blood Return for PE
Hēlo thrombectomy FDA clearance adds integrated blood return for pulmonary embolism. What E2’s two clearances cover, the claims and what is unproven.
Petrelintide Hits Phase 2 Primary Endpoint in Obesity + Type 2 Diabetes: Up to 9.2% Weight Loss (ZUPREME-2)
Zealand Pharma announced on October 7, 2026 that its investigational amylin analog petrelintide met the primary endpoint in the ZUPREME-2 Phase 2 trial in adults with overweight or obesity and…
FDA Approves Hovilpri (Pritelivir) for Drug-Resistant HSV in Immunocompromised Patients
The U.S. FDA approved pritelivir (Hovilpri) on October 9, 2026, for the treatment of mucocutaneous herpes simplex virus (HSV) lesions in immunocompromised adults who did not adequately respond to standard…
FDA Approves Jaypirca (Pirtobrutinib) for First-Line CLL/SLL: HR 0.20 in BRUIN CLL-313 Trial
The U.S. Food and Drug Administration (FDA) approved pirtobrutinib (Jaypirca), Eli Lilly’s non-covalent BTK inhibitor, on October 2, 2026, for the first-line treatment of adults with chronic lymphocytic leukemia (CLL)…
Epcoritamab Plus R-CHOP Cuts Lymphoma Progression Risk by 51% in Landmark Phase 3 Trial
AbbVie and Genmab report Phase 3 Epcore DLBCL-2 results: epcoritamab (Epkinly) added to R-CHOP reduces lymphoma progression or death by 51% (HR 0.49) in newly diagnosed DLBCL. Polivy rival targets…
FDA Approves Teva’s Weltruza: The First Once-Monthly Subcutaneous Olanzapine for Schizophrenia
FDA approved Teva’s Weltruza (olanzapine monthly injection) on October 9, 2026—the first once-monthly subcutaneous olanzapine for schizophrenia. SOLARIS trial: PANSS -11.27 pts. No loading dose, no monitoring required.
FDA Approves Roche’s Tecentriq for Stage III dMMR Colon Cancer: A Major Immunotherapy Breakthrough
The FDA approved Roche’s Tecentriq (atezolizumab) for Stage III dMMR colon cancer as adjuvant treatment, cutting recurrence risk by 50% (HR 0.50) in the ATOMIC Phase 3 trial. Priority Review,…
Aprocitentan Hypertension Study: 2 New Post Hoc Analyses
Aprocitentan hypertension study: two post hoc PRECISION analyses show BP falls in obesity and CKM stages, with kidney markers that need confirming.